Published in Proteomics on October 01, 2004
MAM: more than just a housekeeper. Trends Cell Biol (2009) 4.27
VDAC1: from structure to cancer therapy. Front Oncol (2012) 1.16
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood (2007) 1.11
An investigation into the cytotoxic effects of 13-acetoxysarcocrassolide from the soft coral Sarcophyton crassocaule on bladder cancer cells. Mar Drugs (2011) 0.97
Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in HL-60 cells induced by arsenite treatment. J Proteome Res (2010) 0.93
Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev (2007) 0.92
Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicin. J Proteome Res (2010) 0.85
Proteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: the use of a novel computational method to analyze mass spectrometric profiling. J Matern Fetal Neonatal Med (2008) 0.85
Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther (2016) 0.83
Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. J Proteome Res (2013) 0.82
Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy. Expert Rev Proteomics (2010) 0.81
Proteome alteration induced by hTERT transfection of human fibroblast cells. Proteome Sci (2008) 0.79
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells. Cancer Med (2013) 0.79
A New Fungal Diterpene Induces VDAC1-dependent Apoptosis in Bax/Bak-deficient Cells. J Biol Chem (2015) 0.78
Impact of intracellular ion channels on cancer development and progression. Eur Biophys J (2016) 0.78
Discovery of biomarkers for osteosarcoma by proteomics approaches. Sarcoma (2012) 0.77
News about VDAC1 in Hypoxia. Front Oncol (2016) 0.75
Cytosolic Hsp60 can modulate proteasome activity in yeast. J Biol Chem (2014) 0.75
Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs. Met Based Drugs (2008) 0.75
The Mitochondrial Voltage-Dependent Anion Channel 1, Ca(2+) Transport, Apoptosis, and Their Regulation. Front Oncol (2017) 0.75
Hierridin B Isolated from a Marine Cyanobacterium Alters VDAC1, Mitochondrial Activity, and Cell Cycle Genes on HT-29 Colon Adenocarcinoma Cells. Mar Drugs (2016) 0.75
Synthesis, characterization, and biological activity of platinum II, III, and IV pivaloamidine complexes. J Biol Inorg Chem (2014) 0.75
Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis (2004) 6.97
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A (2009) 4.19
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med (2011) 4.09
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N Engl J Med (2003) 2.21
Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst (2004) 1.84
Spot overlapping in two-dimensional maps: a serious problem ignored for much too long. Proteomics (2005) 1.79
Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: Identification of novel proapoptotic agents. Bioorg Med Chem (2010) 1.63
REST controls self-renewal and tumorigenic competence of human glioblastoma cells. PLoS One (2012) 1.58
The red blood cell proteome and interactome: an update. J Proteome Res (2010) 1.56
Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the SEC23B gene. Hum Mutat (2009) 1.52
"Proteomineering" or not? The debate on biomarker discovery in sera continues. J Proteomics (2011) 1.50
Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol Ther (2008) 1.47
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res (2003) 1.45
Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol Cell Proteomics (2008) 1.41
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis (2005) 1.37
Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol (2012) 1.36
Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol (2010) 1.35
Exploring the hidden human urinary proteome via ligand library beads. J Proteome Res (2005) 1.34
Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr Opin Pharmacol (2007) 1.33
Overview of tumor cell chemoresistance mechanisms. Methods Mol Med (2005) 1.26
Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes. J Biol Chem (2004) 1.26
Proteomic analysis of S-nitrosylated proteins in Arabidopsis thaliana undergoing hypersensitive response. Proteomics (2008) 1.26
Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia (2011) 1.26
Proteomic analysis of human blood serum using peptide library beads. J Proteome Res (2007) 1.22
Harry Belafonte and the secret proteome of coconut milk. J Proteomics (2011) 1.17
In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification. Mol Cell Proteomics (2010) 1.16
The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J Proteomics (2008) 1.13
Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks. Oncogene (2004) 1.12
The art of observing rare protein species in proteomes with peptide ligand libraries. Proteomics (2009) 1.11
Exploring the venom proteome of the western diamondback rattlesnake, Crotalus atrox, via snake venomics and combinatorial peptide ligand library approaches. J Proteome Res (2009) 1.08
New approach based on fuzzy logic and principal component analysis for the classification of two-dimensional maps in health and disease. Application to lymphomas. J Chromatogr A (2003) 1.06
Proteomics as a complementary tool for identifying unintended side effects occurring in transgenic maize seeds as a result of genetic modifications. J Proteome Res (2008) 1.05
RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia (2009) 1.04
Chicken egg yolk cytoplasmic proteome, mined via combinatorial peptide ligand libraries. J Chromatogr A (2008) 1.03
Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells. Eur J Cancer (2006) 1.03
Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med (2011) 1.02
Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol (2009) 1.02
Exploring the platelet proteome via combinatorial, hexapeptide ligand libraries. J Proteome Res (2007) 1.01
Reduction of dynamic protein concentration range of biological extracts for the discovery of low-abundance proteins by means of hexapeptide ligand library. Nat Protoc (2008) 1.00
Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx. J Vasc Interv Radiol (2007) 1.00
Exploring the chicken egg white proteome with combinatorial peptide ligand libraries. J Proteome Res (2008) 0.99
Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol (2004) 0.99
Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther (2008) 0.99
Reducing protein concentration range of biological samples using solid-phase ligand libraries. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.99
Proteome analysis in the clinical chemistry laboratory: myth or reality? Clin Chim Acta (2005) 0.97
Carbamylation of proteins in 2-D electrophoresis--myth or reality? J Proteome Res (2003) 0.96
Urinary prostasin: a candidate marker of epithelial sodium channel activation in humans. Hypertension (2005) 0.96
Targeting RET for thyroid cancer therapy. Biochem Pharmacol (2008) 0.96
Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert Opin Ther Targets (2008) 0.96
Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther (2006) 0.96
The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci (2009) 0.96
In-depth exploration of cow's whey proteome via combinatorial peptide ligand libraries. J Proteome Res (2009) 0.96
Unseen proteome: mining below the tip of the iceberg to find low abundance and membrane proteins. J Proteome Res (2003) 0.94
Soft immobilized pH gradient gels in proteome analysis: a follow-up. Proteomics (2003) 0.94
Beta-elimination: an unexpected artefact in proteome analysis. Proteomics (2003) 0.94
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol Cancer Res (2003) 0.94
Modern strategies for protein quantification in proteome analysis: advantages and limitations. Mass Spectrom Rev (2003) 0.93
Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res (2008) 0.93
Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer (2003) 0.93
Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors. Bioorg Med Chem Lett (2007) 0.93
Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol (2004) 0.93
A new approach for the detection and identification of protein impurities using combinatorial solid phase ligand libraries. J Proteome Res (2006) 0.93
ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968. Cancer Lett (2009) 0.92
Art-loving bugs: the resurrection of Spinello Aretino from Pisa's cemetery. Proteomics (2005) 0.92
Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. J Med Chem (2005) 0.92
Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. Bioorg Med Chem (2012) 0.90
Quantitative proteomics: a review of different methodologies. Eur J Mass Spectrom (Chichester, Eng) (2004) 0.90
A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem (2003) 0.90
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol (2012) 0.90
Differential accumulation of Lhcb gene products in thylakoid membranes of Zea mays plants grown under contrasting light and temperature conditions. Proteomics (2005) 0.89
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem Pharmacol (2011) 0.89
Romancing the "hidden proteome", Anno Domini two zero zero seven. J Chromatogr A (2007) 0.89
Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. Bioorg Med Chem (2010) 0.89
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol (2010) 0.88
Crystal structure of chicken liver basic fatty acid-binding protein complexed with cholic acid. Biochemistry (2004) 0.88
Stenotrophomonas maltophilia SeITE02, a new bacterial strain suitable for bioremediation of selenite-contaminated environmental matrices. Appl Environ Microbiol (2007) 0.88
Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr Pharm Des (2013) 0.88
Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. Neoplasia (2008) 0.88
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents. Clin Cancer Res (2011) 0.88
Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem (2013) 0.88
Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol (2006) 0.88
Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics (2007) 0.88
Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine. Electrophoresis (2003) 0.87
Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis (2003) 0.87